I'm LongbridgeAI, I can summarize articles.VCANBIO's wholly-owned subsidiary Wuhan Guanggu VCANBIO Pharmaceutical Co., Ltd. received the Clinical Trial Application Acceptance Notification for VUM02 injection from the National Medical Products Administration's Drug Evaluation Center on June 23, 2025, with acceptance number CXSL2500507. This injection is a self-developed cryopreserved cell preparation intended for the treatment of severe/critical pneumonia, and currently, there are no similar products on the market globally
According to the Zhitong Finance APP, VCANBIO (600645.SH) announced that its wholly-owned subsidiary Wuhan Guanggu VCANBIO Pharmaceutical Co., Ltd. received the "Acceptance Notice" for the clinical trial application of VUM02 injection issued by the National Medical Products Administration's Center for Drug Evaluation (CDE) on June 23, 2025, with acceptance number CXSL2500507.
VUM02 injection (human umbilical cord-derived mesenchymal stem cell injection) is a cryopreserved cell preparation independently developed by our company. It is a new drug made from selected healthy newborn umbilical cord tissue through in vitro separation, expansion, harvesting, and cryopreservation to prepare human umbilical cord-derived mesenchymal stem cells (UC-MSC). The clinical intended indication is to treat severe/critical pneumonia. As of the announcement date, there are currently no similar cell drugs on the market for the treatment of severe/critical pneumonia globally, and the most advanced similar drugs are in the clinical trial stage